-
Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial Eur. Urol. (IF 25.3) Pub Date : 2024-09-12 Tamim Niazi, Abdenour Nabid, Talia Malagon, Steven Tisseverasinghe, Redouane Bettahar, Rafika Dahmane, Andre-Guy Martin, Marjory Jolicoeur, Michael Yassa, Maroie Barkati, Levon Igidbashian, Boris Bahoric, Robert Archambault, Hugo Villeneuve, Md Mohiuddin
Prostate Cancer Study 5 (PCS5) compared conventional fractionated radiotherapy (CFRT) with hypofractionated radiotherapy (HFRT) in high-risk prostate cancer (PCa) patients, hypothesizing similar toxicity and survival outcomes. This report presents the efficacy analysis.
-
Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology Eur. Urol. (IF 25.3) Pub Date : 2024-09-02 Sandy Figiel, Anthony Bates, David A. Braun, Renu Eapen, Markus Eckstein, Brandon J. Manley, Matthew I. Milowsky, Tom J. Mitchell, Richard J. Bryant, John P. Sfakianos, Alastair D. Lamb
New spatial molecular technologies are poised to transform our understanding and treatment of urological cancers. By mapping the spatial molecular architecture of tumours, these platforms uncover the complex heterogeneity within and around individual malignancies, offering novel insights into disease development, progression, diagnosis, and treatment. They enable tracking of clonal phylogenetics in
-
The Importance of Being Grade 3: A Plea for a Three-tier Hybrid Classification System for Grade in Primary Non–muscle-invasive Bladder Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-08-29 Irene J. Beijert, Oskar Hagberg, Truls Gårdmark, Lars Holmberg, Christel Häggström, Allan Johnston, Matthew Trail, Sami Hamid, Barend A. Dreyer, Luisa Padovani, Roberta Garau, Rami Hasan, Imran Ahmad, David Hendry, Eva M. Compérat, Maximilian Burger, Morgan Rouprêt, Paolo Gontero, Maria J. Ribal, Theo H. van der Kwast, Marko Babjuk, Richard J. Sylvester, Paramananthan Mariappan, Fredrik Liedberg, Bas
Grade is an important determinant of progression in non–muscle-invasive bladder cancer. Although the World Health Organization (WHO) 2004/2016 grading system is recommended, other systems such as WHO1973 and WHO1999 are still widely used. Recently, a hybrid (three-tier) system was proposed, separating WHO2004/2016 high grade (HG) into HG/grade 2 (G2) and HG/G3 while maintaining low grade. We assessed
-
-
Re: In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urologic Cancer Surgery Eur. Urol. (IF 25.3) Pub Date : 2024-07-27 Yabo Xiao, Jing Wu, Zhiyong Chen, Jinbo Chen
-
Metabolic Evaluation and Recurrence Prevention for Urinary Stone Patients: An EAU Guidelines Update Eur. Urol. (IF 25.3) Pub Date : 2024-07-27 Andreas Skolarikos, Bhaskar Somani, Andreas Neisius, Helene Jung, Alec Petřík, Thomas Tailly, Niall Davis, Lazaros Tzelves, Rob Geraghty, Riccardo Lombardo, Carla Bezuidenhout, Giovanni Gambaro
The aim of this review was to define patients who are at high risk of recurrence of urolithiasis, to delineate diagnostic and therapeutic algorithms for each type of stone, and to clarify general guidelines and recommendations for prevention of recurrence.
-
Systematic Prostate Biopsy Versus Perilesional Sampling: If It Isn’t Broke, Why Fix It? Eur. Urol. (IF 25.3) Pub Date : 2024-07-23 Olivier Rouvière, Geert J.L.H. van Leenders, Daniel Eberli, EAU-EANM-ESTRO-ESUR-ISUP-SIOG Prostate Cancer Guidelines Panel
-
[18F]RCCB6 Immuno-Positron Emission Tomography/Computed Tomography for Postoperative Surveillance in Clear Cell Renal Cell Carcinoma: A Pilot Clinical Study Eur. Urol. (IF 25.3) Pub Date : 2024-07-22 Qianyun Wu, Yanfei Wu, You Zhang, Yihui Guan, Gang Huang, Junhua Zheng, Jianjun Liu, Fang Xie, Weijun Wei, Wei Zhai
-
Re: Overall Survival with Adjuvant Pembrolizumab in Renal-cell Carcinoma Eur. Urol. (IF 25.3) Pub Date : 2024-07-22 Zhenbang Liu, Haidar AlSaffar, Sachin Perera, Elio Mazzone, Nathan Lawrentschuk, Renu Eapen, Declan G. Murphy, Marlon L. Perera
-
Re: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial Eur. Urol. (IF 25.3) Pub Date : 2024-07-22 Lars Boesen, Brian F Chapin
-
Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials Eur. Urol. (IF 25.3) Pub Date : 2024-07-17 Daniel E. Spratt, Vinnie Y.T. Liu, Angela Y. Jia, Trevor J. Royce, Howard M. Sandler, Stephanie L. Pugh, Phuoc T. Tran, Felix Y. Feng
-
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial Eur. Urol. (IF 25.3) Pub Date : 2024-07-14 Elizabeth R. Plimack, Catherine Tangen, Melissa Plets, Rutika Kokate, Joanne Xiu, Chadi Nabhan, Eric A. Ross, Erin Grundy, Woonyoung Choi, Colin P.N. Dinney, I-Ling C. Lee, Megan Fong, M. Scott Lucia, Siamak Daneshmand, Dan Theodorescu, Amir Goldkorn, Seth P. Lerner, Thomas W. Flaig, David J. McConkey
We previously reported that tumors harboring any one of four gene mutations (ATM, RB1, FANCC, or ERCC2) were likely to respond to neoadjuvant cisplatin-based chemotherapy (NAC), resulting in cancer-free surgical specimens at the time of cystectomy (pT0). Here, we report our validation of this finding. Using the CARIS 592 Gene Panel (Caris Life Sciences, Phoenix, AZ, USA), we analyzed 105 pre-NAC tumor
-
Re: Vipul Patel, Jacques Marescaux, Marcio Covas Moschovas. The Humanitarian Impact of Telesurgery and Remote Surgery in Global Medicine. Eur Urol. 2024;86:88–9 Eur. Urol. (IF 25.3) Pub Date : 2024-07-06 Chang-Kun Mao, Tao Zhang, Jun-Ting Li
-
Reply to Chang-Kun Mao, Tao Zhang, and Jun-Ting Li’s Letter to the Editor re: Vipul Patel, Jacques Marescaux, Marcio Covas Moschovas. The Humanitarian Impact of Telesurgery and Remote Surgery in Global Medicine. Eur Urol. 2024;86:88–9 Eur. Urol. (IF 25.3) Pub Date : 2024-07-06 Marcio Covas Moschovas, Vipul Patel
-
Reducing or Increasing Overtreatment? How Do We Measure the Impact of Magnetic Resonance Imaging–targeted Biopsy on Prostate Cancer Mortality? Eur. Urol. (IF 25.3) Pub Date : 2024-06-19 Samir S. Taneja
-
Corrigendum to “Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial” [Eur. Eurol. 84(2) (2023) 156–163] Eur. Urol. (IF 25.3) Pub Date : 2024-06-18 Oliver Sartor, Theodore G. Karrison, Howard M. Sandler, Leonard G. Gomella, Mahul Amin, James Purdy, Jeff M. Michalski, Mark G. Garzotto, Nadeem Pervez, Alexander G. Balogh, George B. Rodrigues, Luis Souhami, M. Neil Reaume, Scott G. Williams, Raquibul Hannan, Christopher U. Jones, Eric M. Horwitz, Joseph P. Rodgers, Felix Y. Feng, Seth A. Rosenthal
-
PRECISE v2: An Enhanced Framework To Guide Future Research on the Use of Magnetic Resonance Imaging in Prostate Cancer Active Surveillance Eur. Urol. (IF 25.3) Pub Date : 2024-06-18 Matthew R. Cooperberg
-
Biomarkers in Prostate Cancer Screening: Sometimes “More is More” Eur. Urol. (IF 25.3) Pub Date : 2024-06-18 Arnav Srivastava, Patrick Lewicki, Todd M. Morgan
-
Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial Eur. Urol. (IF 25.3) Pub Date : 2024-06-18 Ruben Raychaudhuri, Makayla DeJong, Matthew Rettig, Evan Y. Yu, Roman Gulati, Michael T. Schweizer, Peter S. Nelson, Colin C. Pritchard, Bruce Montgomery, Heather H. Cheng
-
Rethinking Stone-free Rates and Surgical Outcomes in Endourology: A Point of View from PEARLS Members Eur. Urol. (IF 25.3) Pub Date : 2024-06-17 Frédéric Panthier, Vineet Gauhar, Eugenio Ventimiglia, Jia-Lun Kwok, Etienne Xavier Keller, Olivier Traxer
There is a lack of consensus on definitions for the success of endourological stone treatments. The zero-fragment rate (residual fragments [RFs] <1 mm) is now considered more accurate than the stone-free rate (RFs ≤4 mm). As stone volume may be adopted as the recommended method for preoperative estimation of the stone burden, the volumetric stone-free rate may be superior to standard linear RF measurements
-
Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable? Eur. Urol. (IF 25.3) Pub Date : 2024-06-15 Jason R. Brown, Guru P. Sonpavde, Adam Calaway, Pedro C. Barata
-
Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? Eur. Urol. (IF 25.3) Pub Date : 2024-06-14 Amanda A. Myers, Wei Shen Tan, Valentina Grajales, Hyunsoo Hwang, Kelly K. Bree, Neema Navai, Byron H. Lee, Colin P.N. Dinney, Ashish M. Kamat
-
The Role of Bladder Outlet Obstruction in Male Non-neurogenic Lower Urinary Tract Symptoms—Any Additional News? Eur. Urol. (IF 25.3) Pub Date : 2024-06-14 Stephan Madersbacher, Matthias Oelke
-
High-performing, Accessible, and Affordable Imaging in Metastatic Prostate Cancer: Is Whole-body Magnetic Resonance Imaging the Answer? Eur. Urol. (IF 25.3) Pub Date : 2024-06-12 Sola Adeleke
-
EVEREST: Attempting the Summit with Adjuvant Everolimus To Treat High-risk Renal Cell Carcinoma After Surgery Eur. Urol. (IF 25.3) Pub Date : 2024-06-12 Jens Bedke, Axel Bex
-
All Biochemical Recurrences Are Equal, but Some Are More Equal than Others Eur. Urol. (IF 25.3) Pub Date : 2024-06-12 Verane Achard, Bertrand Tombal
-
Re: Srikala S. Sridhar, Thomas Powles, Miguel. Á. Climent Durán, et al. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance. Eur Urol 2024:85:154–63 Eur. Urol. (IF 25.3) Pub Date : 2024-05-29 Weimin Zhou, Xiongbing Zu, Jiao Hu
-
Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma Eur. Urol. (IF 25.3) Pub Date : 2024-05-29 Iver Nordentoft, Sia Viborg Lindskrog, Karin Birkenkamp-Demtröder, Santiago Gonzalez, Maja Kuzman, Jurica Levatic, Dunja Glavas, Ryan Ptashkin, James Smadbeck, Danielle Afterman, Tomer Lauterman, Yarin Cohen, Zohar Donenhirsh, Iman Tavassoly, Ury Alon, Amanda Frydendahl, Mads Heilskov Rasmussen, Claus Lindbjerg Andersen, Philippe Lamy, Michael Knudsen, Paz Polak, Asaf Zviran, Boris Oklander, Mads Agerbæk
Circulating tumor DNA (ctDNA) can be used for sensitive detection of minimal residual disease (MRD). However, the probability of detecting ctDNA in settings of low tumor burden is limited by the number of mutations analyzed and the plasma volume available. We used a whole-genome sequencing (WGS) approach for ctDNA detection in patients with urothelial carcinoma.
-
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial Eur. Urol. (IF 25.3) Pub Date : 2024-05-29 Primo N. Lara Jr, Catherine Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell Meng, Ajjai Shivaram Alva, Sumanta K. Pal, Igor Puzanov, Joseph I. Clark, Toni K. Choueiri, Neeraj Agarwal, Robert Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian M. Shuch, Seth Lerner, Ian M. Thompson Jr, Christopher W. Ryan
EVEREST is a phase 3 trial in patients with renal cell cancer (RCC) at intermediate-high or very high risk of recurrence after nephrectomy who were randomized to receive adjuvant everolimus or placebo. Longer recurrence-free survival (RFS) was observed with everolimus (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.72–1.00; = 0.051), but the nominal significance level ( = 0.044) was not reached
-
Challenging the Urologist of the Future: Time for a Change? Eur. Urol. (IF 25.3) Pub Date : 2024-05-29 Fabian P. Stangl, Isabel Heidegger, Pia Kraft, Rianne J.M. Lammers, Mark Horvath, Muslim Dogan Deger, Elvira Polo-Alonso, Mike Wenzel, Andres Affentranger, Katrine Schou-Jensen, Lobna Ali, Robert A. Keenan, Anna Cadenar, Laura Gallardo-Zamora, Josias Franco Alva, Domenico Trerè, Georgios Tsampoukas, Peter Hoyerup, Clara Cerrato, Nicolas Raison, Sabine Brookman-May, Juan Luis Vásquez
-
Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging–visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003 Eur. Urol. (IF 25.3) Pub Date : 2024-05-25 Andrew J. Vickers
-
Can an En Bloc Technique Improve Outcomes of Endoscopic Surgery for Non–muscle-invasive Bladder Cancer? Eur. Urol. (IF 25.3) Pub Date : 2024-05-25 Marko Babjuk
-
Reply to Andrew J. Vickers’ Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging–visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003 Eur. Urol. (IF 25.3) Pub Date : 2024-05-24 Alessandro Uleri, Michael Baboudjian, Romain Diamand, Guillaume Ploussard
-
Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Røder’s Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging–visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003 Eur. Urol. (IF 25.3) Pub Date : 2024-05-24 Alessandro Uleri, Michael Baboudjian, Romain Diamand, Guillaume Ploussard
-
-
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe Eur. Urol. (IF 25.3) Pub Date : 2024-05-23 Pieter Vynckier, Lieven Annemans, Sarah Raes, Cheïma Amrouch, Peter Lindgren, Ondřej Májek, Katharina Beyer, Renée C.A. Leenen, Lionne D.F. Venderbos, Frederique Denijs, Meike J. van Harten, Jozien Helleman, Renata Chloupková, Erik Briers, Vera Vasilyeva, Juan Gomez Rivas, Partha Basu, Arunah Chandran, Roderick C.N. van den Bergh, Sarah Collen, Hein Van Poppel, Monique J. Roobol, Members of the PRAISE-U
In Europe, prostate cancer (PCa) is the most common cancer in men. Screening may therefore be crucial to lower health care costs, morbidity, and mortality. This systematic review aimed to provide a contemporary overview of the costs and benefits of PCa screening programmes. A peer-reviewed literature search was conducted, using the PICO method. A detailed search strategy was developed in four databases
-
Prostate-specific Antigen Screening in Limbo: How Low Should We Go? Eur. Urol. (IF 25.3) Pub Date : 2024-05-22 Ian M. Thompson Jr.
-
Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial Eur. Urol. (IF 25.3) Pub Date : 2024-05-22 Kelly N. Fitzgerald, Chung-Han Lee, Martin H. Voss, Maria I. Carlo, Andrea Knezevic, Laura Peralta, Yingbei Chen, Robert A. Lefkowitz, Neil J. Shah, Colette N. Owens, Deaglan J. McHugh, David H. Aggen, Andrew L. Laccetti, Ritesh R. Kotecha, Darren R. Feldman, Robert J. Motzer
Treatment options are limited for patients with non–clear cell renal cell carcinoma (nccRCC). Patients with nccRCC experienced a favorable objective response rate (ORR) in a phase 2 trial of cabozantinib plus nivolumab. We now report updated efficacy and safety results at median follow-up of 34 mo for patients with papillary, unclassified, or translocation-associated RCC. Cabozantinib and nivolumab
-
Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review Eur. Urol. (IF 25.3) Pub Date : 2024-05-22 Adam B. Weiner, Preeti Kakani, Andrew J. Armstrong, Alberto Bossi, Philip Cornford, Felix Feng, Pratik Kanabur, R. Jeffery Karnes, Rana R. Mckay, Todd M. Morgan, Edward M. Schaeffer, Neal Shore, Alison C. Tree, Daniel E. Spratt
Biochemical recurrence (BCR) after primary definitive treatment for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with worse oncologic outcomes, risk factors that impact outcomes can vary significantly, necessitating avenues for risk stratification. We sought to identify prognostic risk factors at the time of recurrence after primary radical prostatectomy or radiotherapy
-
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials Eur. Urol. (IF 25.3) Pub Date : 2024-05-22 Praful Ravi, Wanling Xie, Marc Buyse, Susan Halabi, Philip W. Kantoff, Oliver Sartor, Gert Attard, Noel Clarke, Anthony D'Amico, James Dignam, Nicholas James, Karim Fizazi, Silke Gillessen, Wendy Parulekar, Howard Sandler, Daniel E. Spratt, Matthew R. Sydes, Bertrand Tombal, Scott Williams, Christopher J. Sweeney
Radiotherapy (RT) and long-term androgen deprivation therapy (ltADT; 18–36 mo) is a standard of care in the treatment of high-risk localized/locoregional prostate cancer (HRLPC). We evaluated the outcomes in patients treated with RT + ltADT to identify which patients have poorer prognosis with standard therapy. Individual patient data from patients with HRLPC (as defined by any of the following three
-
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide Eur. Urol. (IF 25.3) Pub Date : 2024-05-20 Alberto Dalla Volta, Francesca Valcamonico, Andrea Zivi, Giuseppe Procopio, Pierangela Sepe, Gianluca Del Conte, Nunzia Di Meo, Silvia Foti, Stefania Zamboni, Caterina Messina, Eleonora Lucchini, Anna Rizzi, Marco Ravanelli, Stefano Calza, Francesca Zacchi, Giovannino Ciccone, Nazareno Suardi, Roberto Maroldi, Davide Farina, Alfredo Berruti
-
Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial Eur. Urol. (IF 25.3) Pub Date : 2024-05-20 Andreas Josefsson, Marianne Månsson, Kimia Kohestani, Vasiliki Spyratou, Jonas Wallström, Mikael Hellström, Hans Lilja, Andrew Vickers, Sigrid V. Carlsson, Rebecka Godtman, Jonas Hugosson
We investigated whether adding 4Kscore as a reflex test to prostate-specific antigen (PSA) could improve the screening algorithm for prostate cancer (PC). In the GÖTEBORG-2 PC screening trial, 38 000men (50–60 yr) were invited to PSA testing and, if elevated, followed by magnetic resonance imaging (MRI). For 571 men with PSA ≥3.0 ng/ml and evaluable outcomes, 4Kscore was calculated. The performance
-
The Humanitarian Impact of Telesurgery and Remote Surgery in Global Medicine Eur. Urol. (IF 25.3) Pub Date : 2024-05-18 Vipul Patel, Jacques Marescaux, Marcio Covas Moschovas
-
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-05-18 Sabine D. Brookman-May, Marc Buyse, Stephen J. Freedland, Branko Miladinovic, Ke Zhang, Wolfgang P. Fendler, Felix Feng, Oliver Sartor, Christopher J. Sweeney
-
Re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.016 Eur. Urol. (IF 25.3) Pub Date : 2024-05-17 Anwar R. Padhani, Frederic Lecouvet, Giuseppe Petralia, Dow-Mu Koh
-
Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh’s Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.016 Eur. Urol. (IF 25.3) Pub Date : 2024-05-17 Alonso Garcia-Ruiz, Carlos Macarro, Joaquin Mateo, Raquel Perez-Lopez
-
Re: External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort Eur. Urol. (IF 25.3) Pub Date : 2024-05-16 Christian D. Fankhauser, Marian S. Wettstein, Christoph Würnschimmel, Maarten van Smeden, Noel W. Clarke
-
Risk-adjusted Screening for Prostate Cancer—Defining the Low-risk Group by Data from the PROBASE Trial Eur. Urol. (IF 25.3) Pub Date : 2024-05-15 Agne Krilaviciute, Rudolf Kaaks, Petra Seibold, Maxime de Vrieze, Jale Lakes, Jan Philipp Radtke, Markus Kuczyk, Nina N. Harke, Jürgen Debus, Christoph A. Fink, Kathleen Herkommer, Jürgen E. Gschwend, Valentin H. Meissner, Axel Benner, Glen Kristiansen, Boris Hadaschik, Christian Arsov, Lars Schimmöller, Gerald Antoch, Frederik L. Giesel, Marcus Makowski, Frank Wacker, Heinz-Peter Schlemmer, Nikolaus
Risk-adjusted screening for prostate cancer (PCa) aims to reduce harms by less frequent retesting, especially in men at a low risk of PCa. Definitions of low risk are based mainly on studies in men starting screening at age 55–60 yr. To identify men at age 45 yr with a low risk of PCa. A population-based, risk-adjusted PCa screening trial was conducted in Germany using baseline prostate-specific antigen
-
Predicting Renal Function following Nephroureterectomy can Impact Timing of Systemic Chemotherapy Eur. Urol. (IF 25.3) Pub Date : 2024-05-14 Carlos Munoz-Lopez, Nityam Rathi, Steven C. Campbell
-
Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging–visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003 Eur. Urol. (IF 25.3) Pub Date : 2024-05-14 Hein V. Stroomberg, Klaus Brasso, Andreas Røder
-
Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study Eur. Urol. (IF 25.3) Pub Date : 2024-05-14 Axel S. Merseburger, Simon Chowdhury, Amit Bahl
-
TP53 Mutations Emerge as a Critical Biomarker in Penile Cancer, Superseding Human Papillomavirus Status Eur. Urol. (IF 25.3) Pub Date : 2024-05-14 Jad Chahoud, Xiaoqing Yu, Andrea Necchi, Philippe E. Spiess
-
Insights into Training Standards for Robot-assisted Surgery and Endourology: A Perspective for Both Urologists and Trainees Eur. Urol. (IF 25.3) Pub Date : 2024-05-14 Nicholas Raison, Prokar Dasgupta, Thomas Knoll
-
Bladder Outlet Obstruction Relief and Symptom Improvement Following Medical and Surgical Therapies for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Systematic Review Eur. Urol. (IF 25.3) Pub Date : 2024-05-14 Massimiliano Creta, Giorgio I. Russo, Naeem Bhojani, Marcus J. Drake, Christian Gratzke, Benoit Peyronnet, Claus Roehrborn, Kari A.O. Tikkinen, Jean-Nicolas Cornu, Ferdinando Fusco
Symptomatic benefit and urodynamic obstruction relief represent relevant outcomes of therapies for lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). We summarized evidence from studies concurrently assessing variations in terms of symptoms severity and invasive urodynamic measures of obstruction following medical and surgical therapies for LUTS/BPH.
-
Re: Clinically Important Differences for Pain and Urinary Symptoms in Urological Chronic Pelvic Pain Syndrome: A MAPP Network Study Eur. Urol. (IF 25.3) Pub Date : 2024-05-13 Gopal H. Badlani
-
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-05-13 Martina Catalano, Matteo Santoni, Giandomenico Roviello
-
Re: Incidence and Survival of Secondary Malignancies after External Beam Radiotherapy for Prostate Cancer in the SEER Database Eur. Urol. (IF 25.3) Pub Date : 2024-05-13 Joseph L. Chin
-
Underactive Bladder According to the European Association of Urology Guidelines Eur. Urol. (IF 25.3) Pub Date : 2024-05-13 Michael Chancellor
-
Keep it Simple: A Proposal for a New Definition of Uncomplicated and Complicated Urinary Tract Infections from the EAU Urological Infections Guidelines Panel Eur. Urol. (IF 25.3) Pub Date : 2024-05-13 Gernot Bonkat, Florian Wagenlehner, Jennifer Kranz
The European Association of Urology Urological Infections Guidelines Panel is proposing a new classification scheme for categorizing urinary tract infections (UTIs) into uncomplicated and complicated types. This classification would provide clarity and facilitate effective clinical management of UTIs, and acknowledges the importance of addressing clinical and sex-specific nuances in the care of individual
-
Re: Actinium-225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer (WARMTH Act): A Multicentre, Retrospective Study Eur. Urol. (IF 25.3) Pub Date : 2024-05-11 Somto Okoli, Oluchi Okoli, Hao Ding, Sola Adeleke